CO6351811A2 - La proteina de tuberculosis rv2386c, composiciones y usos de la misma - Google Patents

La proteina de tuberculosis rv2386c, composiciones y usos de la misma

Info

Publication number
CO6351811A2
CO6351811A2 CO11009237A CO11009237A CO6351811A2 CO 6351811 A2 CO6351811 A2 CO 6351811A2 CO 11009237 A CO11009237 A CO 11009237A CO 11009237 A CO11009237 A CO 11009237A CO 6351811 A2 CO6351811 A2 CO 6351811A2
Authority
CO
Colombia
Prior art keywords
rv2386c
compositions
same
tuberculosis protein
protein sequence
Prior art date
Application number
CO11009237A
Other languages
English (en)
Spanish (es)
Inventor
James E Brown
Pascal Mettens
Dennis Murphy
Original Assignee
Glaxosmithkline Biolog Sa
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa, Glaxo Group Ltd filed Critical Glaxosmithkline Biolog Sa
Publication of CO6351811A2 publication Critical patent/CO6351811A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1289—Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
CO11009237A 2008-07-25 2011-01-27 La proteina de tuberculosis rv2386c, composiciones y usos de la misma CO6351811A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8369908P 2008-07-25 2008-07-25

Publications (1)

Publication Number Publication Date
CO6351811A2 true CO6351811A2 (es) 2011-12-20

Family

ID=41227131

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11009237A CO6351811A2 (es) 2008-07-25 2011-01-27 La proteina de tuberculosis rv2386c, composiciones y usos de la misma

Country Status (23)

Country Link
US (4) US20110206712A1 (enExample)
EP (1) EP2315834B1 (enExample)
JP (2) JP5981138B2 (enExample)
KR (1) KR20110049834A (enExample)
CN (2) CN102165064B (enExample)
AU (1) AU2009273132B2 (enExample)
BR (1) BRPI0916704A2 (enExample)
CA (1) CA2731547C (enExample)
CO (1) CO6351811A2 (enExample)
CY (1) CY1121632T1 (enExample)
DK (1) DK2315834T3 (enExample)
EA (1) EA201100070A1 (enExample)
ES (1) ES2685498T3 (enExample)
HR (1) HRP20181353T1 (enExample)
HU (1) HUE039159T2 (enExample)
IL (1) IL210589A (enExample)
LT (1) LT2315834T (enExample)
MX (1) MX2011000982A (enExample)
PL (1) PL2315834T3 (enExample)
PT (1) PT2315834T (enExample)
SI (1) SI2315834T1 (enExample)
UA (1) UA107329C2 (enExample)
WO (1) WO2010010179A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2207035B1 (en) * 2006-03-14 2013-10-16 Oregon Health and Science University Methods for detecting a mycobacterium tuberculosis infection
WO2009158284A2 (en) * 2008-06-26 2009-12-30 Mayo Foundation For Medical Education And Research Methods and materials for producing immune responses against polypeptides involved in antibiotic resistance
PT2315834T (pt) 2008-07-25 2018-08-10 Glaxosmithkline Biologicals Sa A proteína rv2386c de tuberculose, composições e as suas utilizações
BRPI0916705A2 (pt) 2008-07-25 2015-11-10 Glaxo Group Ltd polipeptídeo isolado, polinucleotídeo isolado, composição farmacêutica, composição imunogênica, método para tratamento ou prevenção de tuberculose, e, usos de um polipeptídeo, e de um polinucleotídeo.
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
WO2013090897A1 (en) * 2011-12-15 2013-06-20 The Trustees Of The University Of Pennsylvania Using adaptive immunity to detect drug resistance
CN104211787A (zh) * 2013-05-31 2014-12-17 中国医学科学院病原生物学研究所 用于结核病诊断和预防的蛋白
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
EP3180353B1 (en) 2014-08-15 2021-09-22 Oxford Immunotec Limited Mycobacterium tuberculosis proteins
CN105572352B (zh) * 2016-02-17 2017-07-28 遵义医学院附属医院 一组结核潜伏感染诊断标志物及其用途
EP3551222B1 (en) 2016-12-07 2024-08-07 GlaxoSmithKline Biologicals SA Process for making a liposome composition comprising a saponin
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
GB2600654B (en) 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel devices
WO2019106192A1 (en) 2017-12-01 2019-06-06 Glaxosmithkline Biologicals Sa Saponin purification
CN108950031A (zh) * 2018-06-29 2018-12-07 周琳 结核分枝杆菌的利福平耐药性诊断标志物及其应用
CN109234414B (zh) * 2018-06-29 2022-05-17 周琳 结核分枝杆菌的对氨基水杨酸耐药性诊断标志物及其应用
CN108866213A (zh) * 2018-06-29 2018-11-23 周琳 结核分枝杆菌利福平耐药性诊断标志物及其应用
JP7640473B2 (ja) 2019-06-05 2025-03-05 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製
EP3983011A1 (en) * 2019-06-14 2022-04-20 Statens Serum Institut Fusion proteins for tuberculosis vaccines
CN112457410B (zh) * 2020-11-05 2023-04-07 迈克生物股份有限公司 用于结核分枝杆菌感染检测的抗原组合物
DE202022102137U1 (de) 2022-04-21 2022-04-28 Damayanthi Dalu Eine neue Zusammensetzung zur Behandlung von Tuberkulose
CN115073612B (zh) * 2022-06-22 2024-09-27 宁夏大学 一种结核分枝杆菌Zera-71cA蛋白纳米颗粒、制备方法及其用途
CN115725607B (zh) * 2022-07-14 2023-11-28 山东第一医科大学附属省立医院(山东省立医院) 一种鼻疽诺卡菌的致病靶基因及其应用
CN120058854A (zh) * 2025-03-05 2025-05-30 北京知筹科技有限公司 一种调节低密度脂蛋白受体相关蛋白（lrp）的多肽及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6592877B1 (en) 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6613881B1 (en) 1997-05-20 2003-09-02 Corixa Corporation Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
KR100797876B1 (ko) 1998-04-07 2008-01-24 코릭사 코포레이션 마이코박테리움 튜베르쿨로시스 항원의 융합 단백질 및이의 용도
AU2001241738A1 (en) 2000-02-25 2001-09-03 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
DE60139963D1 (de) 2000-06-20 2009-10-29 Corixa Corp Fusionsproteine aus mycobakterium tuberculosis
US20040121322A9 (en) 2001-02-22 2004-06-24 Cole Stewart T. Comparative mycobacterial genomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses
US7026465B2 (en) 2002-02-15 2006-04-11 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis
US20030236393A1 (en) 2002-03-22 2003-12-25 United States Of America Dept Of Vetrans Affairs Virulence genes of M. marinum and M. tuberculosis
KR101178776B1 (ko) 2004-02-06 2012-09-07 카운슬 오브 사이언티픽 앤드 인더스트리얼 리서치 치료학적 잠재성을 가진 어드헤신 및 어드헤신계 단백질을 동정하기 위한 컴퓨터 장치
SI2457926T1 (sl) * 2005-04-29 2015-01-30 Glaxosmithkline Biologicals S.A. Nov postopek za preprečevanje ali zdravljenje infekcije z M. tuberculosis
WO2008007942A1 (en) 2006-07-10 2008-01-17 Het Nederlands Kanker Instituut Means and methods for manipulating sequential phagolysomal-cytosolic translocation of mycobacteria, and uses thereof
CA2679410C (en) 2007-03-02 2017-01-17 Glaxosmithkline Biologicals S.A. Novel method and compositions
WO2010010178A1 (en) 2008-07-25 2010-01-28 Glaxosmithkline Biologicals S.A The tuberculosis rv2707c protein, compositions and uses thereof
PT2315834T (pt) 2008-07-25 2018-08-10 Glaxosmithkline Biologicals Sa A proteína rv2386c de tuberculose, composições e as suas utilizações
BRPI0916705A2 (pt) 2008-07-25 2015-11-10 Glaxo Group Ltd polipeptídeo isolado, polinucleotídeo isolado, composição farmacêutica, composição imunogênica, método para tratamento ou prevenção de tuberculose, e, usos de um polipeptídeo, e de um polinucleotídeo.
AU2009273130B2 (en) 2008-07-25 2014-10-16 Glaxo Group Limited Novel compositions and methods
KR20170072366A (ko) 2009-04-24 2017-06-26 스태튼스 세룸 인스티튜트 재활성화를 예방하기 위한 결핵 백신
WO2010132112A2 (en) 2009-05-14 2010-11-18 Wisconsin Alumni Research Foundation Immunogenic compositions against tuberculosis
UA110103C2 (uk) 2010-01-27 2015-11-25 Ґлаксосмітклайн Байолоджікалз С.А. Модифікований туберкульозний антиген

Also Published As

Publication number Publication date
ES2685498T3 (es) 2018-10-09
WO2010010179A1 (en) 2010-01-28
LT2315834T (lt) 2018-09-10
CN106866801A (zh) 2017-06-20
US20140086948A1 (en) 2014-03-27
JP6104326B2 (ja) 2017-03-29
UA107329C2 (uk) 2014-12-25
CA2731547C (en) 2019-04-30
JP2016000734A (ja) 2016-01-07
JP2011528896A (ja) 2011-12-01
US20140314802A1 (en) 2014-10-23
JP5981138B2 (ja) 2016-08-31
US10286053B2 (en) 2019-05-14
IL210589A0 (en) 2011-03-31
EP2315834A1 (en) 2011-05-04
AU2009273132B2 (en) 2015-09-03
US20110206712A1 (en) 2011-08-25
PT2315834T (pt) 2018-08-10
CY1121632T1 (el) 2020-07-31
MX2011000982A (es) 2011-03-02
DK2315834T3 (en) 2018-08-20
CA2731547A1 (en) 2010-01-28
BRPI0916704A2 (pt) 2020-08-18
KR20110049834A (ko) 2011-05-12
CN102165064A (zh) 2011-08-24
EA201100070A1 (ru) 2011-10-31
AU2009273132A1 (en) 2010-01-28
HRP20181353T1 (hr) 2018-10-19
US9480735B2 (en) 2016-11-01
EP2315834B1 (en) 2018-06-13
PL2315834T3 (pl) 2018-12-31
CN102165064B (zh) 2017-06-20
SI2315834T1 (sl) 2018-09-28
US20170065697A1 (en) 2017-03-09
IL210589A (en) 2015-05-31
HUE039159T2 (hu) 2018-12-28

Similar Documents

Publication Publication Date Title
CO6400198A2 (es) Composiciones y metodos novedosos
CO6341637A2 (es) \\\\\\\"composiciones y metodos novedosos\\\\\\\"
CR11580A (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf
EA201100070A1 (ru) Туберкулезный белок rv2386c, композиции и их применения
UY33204A (es) Metodos y composiciones usando polipeptidos de fusion de fgf23
AR125326A2 (es) Composiciones de neisseria meningitidis y métodos de las mismas
CL2020000428A1 (es) Preparación de exosomas terapéuticos mediante el uso de proteínas de membrana.
CL2010001426A1 (es) Compuestos derivados de triciclos, inhibidores de la proteina quinasa; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades oncologicas e inmunologicas.
PE20142451A1 (es) Composiciones de conjugados de xten y metodos para realizar las mismas
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
CL2010001569A1 (es) Pestivirus atenuado mediante la mutacion conjunta de las proteinas e erns y n pro.composicion inmunogenica y vacuna que lo comprende, metodo para atenuar pestivirus basado en la supresion de la dimerizacion de la proteina e rns y la ianactivacion de la proteina n pro.
MX2009012343A (es) Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello.
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
BRPI0508421A (pt) sistemas de transporte biológico de múltiplos componentes
EA201171494A1 (ru) Миметики белка smac
GT200900163A (es) Nuevos compuestos y sus efectos sobre el conductismo de la alimentacion.
MX2016003530A (es) Proteina de fusion.
CL2008000910A1 (es) Proteina de fusion que comprende una proteina que corta el peptido beta amiloide; composicion farmaceutica que la comprende, y su uso para prevenir y/o tratar enfermedades relacionadas con el peptido beta amiloide.
AR083126A1 (es) Composicion vacunal para el control de las infestaciones por ectoparasitos
AR088512A1 (es) Anticuerpos dirigidos contra el tnf
ECSP10010211A (es) Composición
CL2022001035A1 (es) Composiciones y métodos para minimizar la pérdida de proteínas a concentraciones de proteínas bajas
BRPI0606687A2 (pt) composições nutracêuticas
CL2009001083A1 (es) Variantes de receptores de la proteina c3 de complemento (crig), molecula quimerica y composicion farmaceutica que las comprende; uso de las variantes para preparar un medicamento para prevenir o tratar una enfermedad asociada al complemento, tal como una enfermedad inflamatoria o autoinmune.
AR104952A1 (es) Bioconjugados y usos de los mismos

Legal Events

Date Code Title Description
FC Application refused